All Eyes On ABTECT After More Positive Data On Abivax’s Obefazimod
Analysts claim the French biotech is leading the oral IBD landscape and are waiting for a mega-deal centered on the miR-124 up-regulator.
Scrip - May 26, 2026

Stryker Launches Pangea Plating System To Europe Two Years After US Debut
Stryker's Pangea Plating System has reached Europe, two years after its US debut. With its first clinical case completed in London, the platform now enters a $7.8bn trauma fixation market – and into a direct fight with DePuy Synthes, Zimmer Biomet and entrenched surgeon loyalties.
Medtech Insight - May 26, 2026

Pipeline Watch: Thirteen Approvals And Three Phase III Readouts
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Scrip - May 26, 2026

Irish CJEU Referral Offers Route To Challenge UWWTD
The Irish High Court’s referral to the CJEU of questions over the validity of the EU Urban Wastewater Treatment Directive’s extended producer responsibility scheme offers the off-patent industry another route to challenge the controversial legislation.
Generics Bulletin - May 26, 2026

Lilly Plans Phase II For VERVE-102 Gene-Editing Therapy After Early LDL-C Data
While early data for VERVE-102 mark another step in Lilly's push into cardiovascular gene editing, analysts question the need for a one-and-done therapy to lower LDL-C given existing treatment options.
Scrip - May 26, 2026

Lupin Downs Otsuka On US Jynarque Appeal
Lupin has prevailed at the Federal Circuit in a patent dispute involving Otsuka’s Jynarque, preserving a non-infringement win and invalidating asserted tolvaptan synthesis claims.
Generics Bulletin - May 26, 2026

MHRA’s Premarket SI: Agency Foresees No Major WTO Roadblocks
MHRA’s Rob Reid spoke to Medtech Insight on UK and EU medtech regulatory progress after his panel on reliance at the MedTech Forum 2026.
Medtech Insight - May 26, 2026

NICE Says Advanced Liver-Preserving Devices Will Boost Transplant Equality
Four machine perfusion technologies have been recommended for routine NHS use in draft guidance that aims to address the liver transplant “postcode lottery.”
Medtech Insight - May 26, 2026

Against Specialist Tide, Anthropic Backs A Generalist Claude for Biopharma’s R&D Stack
Anthropic is betting that a generalist Claude trained on biology, backed by a $400m biotech acquisition, an in-house wet lab and a Novartis-CEO board seat, can become biopharma’s end-to-end AI partner for drug discovery.
In Vivo - May 26, 2026

Over The Counter: How Agentic AI Changes The OTC Marketing Playbook, With IQVIA’s Volker Spitzer
In part two of this Over the Counter interview with IQVIA Consumer Health's Volker Spitzer, we turn to what agentic AI means in practice for consumer health marketers, covering brand strategy, industry readiness, risk management, and realistic timelines for when this shift is likely to arrive.
HBW Insight - May 26, 2026

In Case You Missed It: ASCO Preview
The oncology conference promises some significant data readouts across pancreatic, breast and lung cancers, lymphoma, myeloma and more.
Scrip - May 26, 2026

Impact Of China’s New Data Protection On Corporate Strategies, Deals
New data protection measures released by China’s drug regulator could influence future licensing deals for innovative assets originating in the country, particularly royalty terms, a law firm predicts.
Scrip - May 26, 2026

Review Of NAD+ Supplement Ad Claims Leaves Ingredient Pioneer Niagen ‘Deeply Disappointed’
BBB National Programs’ appeals board upholds National Advertising Division decision that Niagen Bioscience should discontinue or modify challenged ad claims for health benefits including heart, brain, immunity, metabolism and reproductive as well as anti-aging.
HBW Insight - May 26, 2026